SCHEMBL4476354

SCHEMBL4476354

Nc1cnc(-c2ccc(Cl)cc2Cl)cn1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.51
HSP90AB1 P08238 2/20 0.51
ALOX5AP P20292 12/20 0.51
FEN1 P39748 11/20 0.51
LMNA P02545 1/20 0.49
KDM4E B2RXH2 2/20 0.44
RAB9A P51151 2/20 0.44
MGAM O43451 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CLK1 P49759 1/20 0.43
PTPN1 P18031 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15916237 0.83 FEN1 (0.63) ALOX5APFEN1
SCHEMBL4477259 0.83 ALOX5AP (0.49) ALOX5APFEN1
SCHEMBL14988388 0.79 HSP90AA1 (0.51) HSP90AA1HSP90AB1LMNAKDM4ERAB9A
SCHEMBL4469279 0.79 HSP90AA1 (0.44) HSP90AA1HSP90AB1LMNAKDM4ERAB9A
SCHEMBL2030727 0.78 FEN1 (0.66) HSP90AA1HSP90AB1ALOX5APFEN1
SCHEMBL4498898 0.75 MAP4K4 (0.57) HSP90AA1HSP90AB1FEN1KDM4ERAB9A
SCHEMBL4474343 0.75 HSP90AA1 (0.41) HSP90AA1HSP90AB1LMNAKDM4ERAB9A
Water SCHEMBL7027042 0.75 SCN2A (0.53) ALOX5APFEN1ALDH1A1
SCHEMBL3747046 0.73 ALPL (0.52) KDM4ERAB9AALDH1A1NPC1
SCHEMBL2322762 0.73 SLC6A2 (0.49) ALOX5APFEN1KDM4ERAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592358-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-22 US disclosed
EP-1737823-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2007-01-03 EP disclosed
WO-2005103002-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO disclosed
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234101-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 HSP90AA1 4313/4885HSP90AB1 4644/4885ALOX5AP 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.